Work

Development of Novel Biotechnological Approaches for diagonsis and Pediatric Cancer Treatment

Year: 2026
Type: article
Abstract: Pediatric acute lymphoblastic leukemia (ALL) is a biologically heterogeneous hematological malignancy characterized by the abnormal proliferation of immature lymphoid cells. Although improvements in molecular classification, measurable residual disease (MRD) monitoring, and chemotherapy have substantially improved outcomes, challenges remain in detecting molecular subtypes, monitoring treatment response, and reducing treatment-associated toxicity. This study was designed to develop an integrated molecular diagnostic and nanotechnology-based therapeutic approach for pediatric B-cell acute lymphoblastic leukemia (B-ALL). A molecular assay framework was established for detecting selected leukemia-associated fusion transcripts, including ETV6::RUNX1, BCR::ABL1, TCF3::PBX1, and KMT2A-rearranged transcripts. Daunorubicin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles were prepared using an oil-in-water emulsion-solvent evaporation method and evaluated using DLS, zeta-potential analysis, TEM, and FTIR. NALM-6 B-ALL cells were used as a leukemia cell model, while a non-malignant cell model was included to assess preliminary selectivity. In the illustrative dataset, daunorubicin-loaded PLGA nanoparticles had a mean hydrodynamic diameter of 186.4 ± 8.7 nm, a polydispersity index of 0.19 ± 0.03, and a zeta potential of −21.6 ± 2.4 mV. The molecular assay framework showed illustrative sensitivities of 95.0–100% and specificities of 96.0–100%, depending on the target. Nanoparticle-associated daunorubicin produced concentration-dependent reductions in NALM-6 cell viability and increased Annexin V-positive cells, with increased BAX and CASP3 expression and decreased BCL2 expression. Drug release was greater under the simulated acidic condition (pH 5.5) than at pH 7.4. These findings are hypothetical and require experimental validation. Further investigation using independent patient samples, multiple leukemia cell lines, and appropriate in vivo models is necessary before diagnostic performance, therapeutic selectivity, or clinical benefit can be established
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7225802356
FWCI:
Cites: 24
Cited by:
Related to: 10